ASTRAZENECA PHARMA has announced its results for the year ended March 2018. Let us have a look at the detailed performance review of the company during FY17-18.
No. of Mths Year Ending | 12 Mar-17* | 12 Mar-18* | % Change | |
---|---|---|---|---|
Net Sales | Rs m | 5,437 | 5,710 | 5.0% |
Other income | Rs m | 144 | 123 | -14.9% |
Total Revenues | Rs m | 5,581 | 5,833 | 4.5% |
Gross profit | Rs m | 369 | 463 | 25.3% |
Depreciation | Rs m | 158 | 147 | -6.9% |
Interest | Rs m | 0 | 0 | 0.0% |
Profit before tax | Rs m | 355 | 438 | 23.4% |
Tax | Rs m | 155 | 179 | 15.8% |
Profit after tax | Rs m | 201 | 259 | 29.2% |
Gross profit margin | % | 6.8 | 8.1 | |
Effective tax rate | % | 43.5 | 40.8 | |
Net profit margin | % | 3.6 | 4.4 |
No. of Mths Year Ending | 12 Mar-17* | 12 Mar-18* | % Change | |
---|---|---|---|---|
Networth | Rs m | 2,229 | 2,469 | 10.8 |
Current Liabilities | Rs m | 1,903 | 2,070 | 8.7 |
Long-term Debt | Rs m | 0 | 0 | 0.0 |
Total Liabilities | Rs m | 4,155 | 4,605 | 10.8 |
Current assets | Rs m | 2,516 | 3,209 | 27.6 |
Fixed Assets | Rs m | 917 | 790 | -13.8 |
Total Assets | Rs m | 4,155 | 4,605 | 10.8 |
Particulars | No. of months | 12 | 12 | % Change |
---|---|---|---|---|
Year Ending | Mar-17 | Mar-18 | ||
Cash Flow from Operating Activities | Rs m | 381 | 88 | -76.9% |
Cash Flow from Investing Activities | Rs m | 3 | -94 | - |
Cash Flow from Financing Activities | Rs m | 0 | 0 | 0.0% |
Net Cash Flow | Rs m | 384 | -6 | - |
No. of Mths Year Ending | 12 Mar-17* | 12 Mar-18* | |
---|---|---|---|
Sales per share (Unadj.) | Rs | 217.5 | 228.4 |
TTM Earnings per share | Rs | 8.0 | 10.4 |
Diluted earnings per share | Rs | 8.0 | 10.4 |
Price to Cash Flow | x | 138.5 | 122.3 |
TTM P/E ratio | x | 103.9 | 103.9 |
Price / Book Value ratio | x | 11.9 | 10.9 |
Market Cap | Rs m | 49,695 | 49,695 |
Dividends per share (Unadj.) | Rs | 0.0 | 0.0 |
Current Ratio: The company's current ratio improved and stood at 1.6x during FY18, from 1.3x during FY17. The current ratio measures the company's ability to pay short-term and long-term obligations.
Return on Equity (ROE): The ROE for the company improved and stood at 10.5% during FY18, from 9.0% during FY18. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.
Return on Capital Employed (ROCE): The ROCE for the company improved and stood at 17.7% during FY18, from 15.9% during FY17. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.
Return on Assets (ROA): The ROA of the company improved and stood at 5.6% during FY18, from 4.8% during FY17. The ROA measures how efficiently the company uses its assets to generate earnings.
No. of Mths Year Ending | 12 Mar-17* | 12 Mar-18* | |
---|---|---|---|
Current ratio | x | 1.3 | 1.6 |
Debtors’ Days | Days | 29 | 35 |
Interest coverage | x | 0.0 | 0.0 |
Debt to equity ratio | x | 0.0 | 0.0 |
Return on assets | % | 4.8 | 5.6 |
Return on equity | % | 9.0 | 10.5 |
Return on capital employed | % | 15.9 | 17.7 |
To see how ASTRAZENECA PHARMA has performed over the last 5 years, please visit here.
Over the last one year, ASTRAZENECA PHARMA share price has moved up from Rs 926.5 to Rs 1,987.8, registering a gain of Rs 1,061.3 or around 114.5%.
(To know more, check out historical annual results for ASTRAZENECA PHARMA and quarterly results for ASTRAZENECA PHARMA)
For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
More Views on NewsMy new guide will show you the huge potential in future proof businesses.
The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Ajit Dayal on the investing strategy for 2021 and beyond.
More
| |
Equitymaster requests your view! Post a comment on "ASTRAZENECA PHARMA 2017-18 Annual Report Analysis". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!